The role of REST in the pathogenesis of uterine fibroids
The role of REST in the pathogenesis of uterine fibroids
批准号:
8720039
负责人:
Vargheese Mani Chennathukuzhi
金额:
$34.31万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-12 至 2018-04-30
关键词:
BenignBindingBrainCell ProliferationCellsChIP-seqClinicalCommon NeoplasmDataESR1 geneEnvironmental Risk FactorEpigenetic ProcessEstrogensEtiologyExposure toFemaleFibroid TumorFutureG-Protein-Coupled ReceptorsGene ExpressionGene TargetingGenesGenetic ModelsGenetic RiskGoalsGrowthHumanHysterectomyIn VitroKnockout MiceKnowledgeLaboratoriesLeiomyomaLigandsMethodsMolecularMolecular TargetMusMyometrialNeuronsNuclearPI3K/AKTPathogenesisPathway interactionsPerinatalPeripheralPharmaceutical PreparationsPhenocopyPhenotypePlayPre-Clinical ModelProteinsQuality of lifeRegulationRepressionRepressor ProteinsResearchRestRoleSignal PathwaySignal TransductionSmooth Muscle MyocytesTestingTissuesTransgenic OrganismsTumor Suppressor ProteinsUnited StatesUterine FibroidsUterusWomanWorkcostdrug developmentdrug discoveryfunctional lossgain of functionhuman FRAP1 proteinin vivoin vivo Modelmouse modelmyometriumneoplastic cellnoveloverexpressionpre-clinicalprolactin-releasing peptidepromoterpublic health relevancereproductivetherapy developmenttranscription factortumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Uterine fibroids (leiomyomas) are benign smooth muscle cell (SMC) tumors of the myometrium. Leiomyomas represent the most frequent clinical indication for hysterectomy that often prematurely ends a woman's reproductive capability. In the year 2010, the estimated annual cost of uterine fibroid tumors in the United States was $5.9-34.4 billion. Yet in spite of this, there are currently no approved drugs that can provide effectiv, long-term treatment for these tumors. There is an unmet need to identify molecular targets for the development of therapies to treat uterine fibroids. The long-term goal of our research is to understand the molecular pathogenesis of uterine leiomyomas. Dysregulated PI3K/AKT pathway leading to the activation of mTOR has been suggested to play an essential role in the pathogenesis of leiomyomas. Our preliminary data suggest that GPR10, a GPCR normally silenced in the periphery by the tumor suppressor REST/ NRSF, is near ubiquitously over-expressed human leiomyomas. Further, REST protein is dramatically reduced in leiomyomas. Crucial to the current project, the activation of GPR10, or the loss of REST is suggested to trigger PI3K/AKT signaling and tumor cell proliferation. We hypothesize that the loss of REST leads to GPR10 expression in leiomyomas and this aberrant gene expression functionally promotes cell proliferation contributing to the pathogenesis of uterine fibroids. The current project will establish the functional role that the loss of REST has on the pathogenesis of uterine
fibroids using in vitro methods and novel in vivo genetic models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
REST/NRSF, miRNAs, and tissue remodeling in adenomyosis pathophysiology
-
批准号:10277800
-
项目类别:
-
资助金额:$64.27万
-
财政年份:2021
-
负责人:Vargheese Mani Chennathukuzhi
-
依托单位:
REST/NRSF, miRNAs, and tissue remodeling in adenomyosis pathophysiology
-
批准号:10617304
-
项目类别:
-
资助金额:$63.62万
-
财政年份:2021
-
负责人:Vargheese Mani Chennathukuzhi
-
依托单位:
Allosteric CDK2 inhibitor Discovery and Development for Male Contraception
-
批准号:10018520
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2019
-
负责人:Vargheese Mani Chennathukuzhi
-
依托单位:
Small molecule GPR10 antagonists for the treatment of uterine fibroids
-
批准号:9759969
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2018
-
负责人:Vargheese Mani Chennathukuzhi
-
依托单位:
Cell-cycle regulatory kinases as targets for male contraceptive drug development
-
批准号:9253022
-
项目类别:
-
资助金额:$30.25万
-
财政年份:2014
-
负责人:Vargheese Mani Chennathukuzhi
-
依托单位:
The role of REST in the pathogenesis of uterine fibroids
-
批准号:9261556
-
项目类别:
-
资助金额:$33.53万
-
财政年份:2013
-
负责人:Vargheese Mani Chennathukuzhi
-
依托单位:
The role of REST in the pathogenesis of uterine fibroids
-
批准号:9055746
-
项目类别:
-
资助金额:$33.19万
-
财政年份:2013
-
负责人:Vargheese Mani Chennathukuzhi
-
依托单位:
The role of REST in the pathogenesis of uterine fibroids
-
批准号:8596606
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2013
-
负责人:Vargheese Mani Chennathukuzhi
-
依托单位:
H2-Gamendazole analogues as reversible non-hormonal male contraceptive agents
-
批准号:9127311
-
项目类别:
-
资助金额:$25.94万
-
财政年份:2012
-
负责人:Vargheese Mani Chennathukuzhi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: